Camidanlumab tesirine
- Generic Name
- Camidanlumab tesirine
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1853239-04-9
- Unique Ingredient Identifier
- LYJ1AEJ9YH
- Background
Camidanlumab tesirine is under investigation in clinical trial NCT04639024 (ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN).
- Associated Conditions
- -
- Associated Therapies
- -
Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-08-12
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- ADC Therapeutics S.A.
- Target Recruit Count
- 117
- Registration Number
- NCT04052997
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
🇺🇸Cleveland Clinic - Taussig Cancer Center, Cleveland, Ohio, United States
Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2015-05-04
- Last Posted Date
- 2021-07-13
- Lead Sponsor
- ADC Therapeutics S.A.
- Target Recruit Count
- 133
- Registration Number
- NCT02432235
- Locations
- 🇺🇸
Cancer Therapy and Research Center at The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
🇺🇸Froedtert Hospital/Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.